Main Menu

BiomX Inc.


Rigrodsky Law, P.A. is investigating BiomX Inc. (“BiomX”) regarding possible breaches of fiduciary duties and other violations of law related to BiomX’s agreement to be acquired by Adaptive Phage Therapeutics. Under the terms of the agreement, BiomX will issue 9,164,967 shares of BiomX common stock, 40,471 shares of Series X Preferred Stock convertible into 40,471,000 shares of BiomX common stock and warrants exercisable for 2,166,497 shares of BiomX common stock.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 07/17/2024

* Indicates a required field.

Back to Page